Importantly, the secondary mutations and genetic alterations observed in de novo germline BRCA2-mutant prostate cancers are more similar to those observed in sporadic prostate cancers from advanced prostate cancers after extensive treatment than those observed in treatment-naïve sporadic prostate cancers [30,418]. The gene discussed is BRCA2; the disease is Familial prostate cancer.